LORSTAT

This brand name is authorized in Australia, New Zealand.

Active ingredients

The drug LORSTAT contains one active pharmaceutical ingredient (API):

1	Atorvastatin UNII A0JWA85V8F - ATORVASTATIN
	Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.
	Read more about Atorvastatin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AA05	Atorvastatin	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AA HMG CoA reductase inhibitors
Discover more medicines within C10AA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8213G, 8214H, 8215J, 8521L, 9230T, 9231W, 9232X, 9233Y
NZ	Medicines and Medical Devices Safety Authority	17306, 17307, 17308, 17309